SCHEMBL20522846

SCHEMBL20522846

O=C(OCC1(C=NO)CCCc2cc(Cl)ccc21)c1ccc(Br)cc1

nearest known ligand 0.35

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ KDM4C Q9H3R0 1/20 0.35
▸ KDM1A O60341 1/20 0.34
▸ MAPT P10636 1/20 0.34
▸ TDP1 Q9NUW8 1/20 0.34
▸ MCL1 Q07820 2/20 0.33
▸ SIGMAR1 Q99720 2/20 0.32
▸ SMN1; SMN2 Q16637 2/20 0.32
▸ GAA P10253 1/20 0.32
▸ NPSR1 Q6W5P4 1/20 0.32
▸ BCL2L11 O43521 1/20 0.32
▸ HDAC1 Q13547 4/20 0.32
▸ HDAC6 Q9UBN7 4/20 0.32
▸ PRKCA P17252 1/20 0.32
▸ PRKCE Q02156 1/20 0.32
▸ RASGRP3 Q8IV61 1/20 0.32
▸ CHRNB2 P17787 1/20 0.31
▸ CHRNA7 P36544 1/20 0.31
▸ CHRNA4 P43681 1/20 0.31
▸ RAB9A P51151 2/20 0.31
▸ NPC1 O15118 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20522844 1.00 KDM4C (0.35) KDM4CKDM1AMAPTTDP1MCL1
SCHEMBL17542330 0.90 KDM1A (0.37) KDM4CKDM1AMAPTTDP1MCL1
SCHEMBL17542332 0.90 KDM1A (0.37) KDM4CKDM1AMAPTTDP1MCL1
SCHEMBL17542336 0.80 KDM4C (0.39) KDM4CKDM1AMAPTTDP1MCL1
SCHEMBL17542334 0.80 KDM4C (0.39) KDM4CKDM1AMAPTTDP1MCL1
SCHEMBL26194440 0.80 SMN1; SMN2 (0.39) KDM4CKDM1AMAPTTDP1MCL1
SCHEMBL21930213 0.79 SIGMAR1 (0.42) KDM4CKDM1AMAPTTDP1MCL1
SCHEMBL21930565 0.79 SIGMAR1 (0.42) KDM4CKDM1AMAPTTDP1MCL1
SCHEMBL19285358 0.73 MAP3K14 (0.42) MAPTNPSR1PRKCAPRKCERASGRP3
SCHEMBL29554248 0.73 MAP3K14 (0.42) MAPTNPSR1PRKCAPRKCERASGRP3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3601297-B9 COMPOUNDS THAT INHIBIT MCL-1 PROTEIN AMGEN INC (US) 2023-05-24 — — EP disclosed
EP-3601297-B1 COMPOUNDS THAT INHIBIT MCL-1 PROTEIN AMGEN INC (US) 2022-10-19 — — EP disclosed
US-11224601-B1 Compounds that inhibits MCL-1 protein AMGEN INC. (US) 2022-01-18 — — US disclosed
US-10821115-B2 Compounds that inhibit Mcl-1 protein AMGEN INC. (US) 2020-11-03 — — US disclosed
US-20200171043-A1 COMPOUNDS THAT INHIBIT MCL-1 PROTEIN AMGEN INC. (US) 2020-06-04 — — US disclosed
US-10632128-B2 Compounds that inhibit Mcl-1 protein AMGEN INC. (US) 2020-04-28 — — US disclosed
EP-3601297-A1 COMPOUNDS THAT INHIBIT MCL-1 PROTEIN Amgen Inc. (US) 2020-02-05 — — EP disclosed
US-20190201412-A1 COMPOUNDS THAT INHIBIT MCL-1 PROTEIN AMGEN INC. (US) 2019-07-04 — — US disclosed
US-10300075-B2 Compounds that inhibit MCL-1 protein AMGEN INC. (US) 2019-05-28 — — US disclosed
US-20180289720-A1 COMPOUNDS THAT INHIBIT MCL-1 PROTEIN AMGEN INC. (US) 2018-10-11 — — US disclosed
WO-2018183418-A1 COMPOUNDS THAT INHIBIT MCL-1 PROTEIN AMGEN INC. (US) 2018-10-04 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190201412-A1 COMPOUNDS THAT INHIBIT MCL-1 PROTEIN MCL1, BCL9, BCL2L1 KDM4C 3542/4885KDM1A 1229/4885MAPT 3626/4885
US-10821115-B2 Compounds that inhibit Mcl-1 protein MCL1, BCL9, BCL2L1 KDM4C 3542/4885KDM1A 1229/4885MAPT 3626/4885
US-20180289720-A1 COMPOUNDS THAT INHIBIT MCL-1 PROTEIN MCL1, BCL9, BCL2L1 KDM4C 3542/4885KDM1A 1229/4885MAPT 3626/4885
US-10632128-B2 Compounds that inhibit Mcl-1 protein MCL1, BCL9, BCL2L1 KDM4C 3542/4885KDM1A 1229/4885MAPT 3626/4885
US-10300075-B2 Compounds that inhibit MCL-1 protein MCL1, BCL9, BCL2L1 KDM4C 3542/4885KDM1A 1229/4885MAPT 3626/4885
US-20200171043-A1 COMPOUNDS THAT INHIBIT MCL-1 PROTEIN MCL1, BCL9, BCL2L1 KDM4C 3542/4885KDM1A 1229/4885MAPT 3626/4885
US-11224601-B1 Compounds that inhibits MCL-1 protein MCL1, BCL9, BCL2L1 KDM4C 3544/4885KDM1A 1242/4885MAPT 3650/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback